Global Capillariasis Market

Capillariasis Comprehensive Study by Type (Capillaria Hepatica, Capillaria Philippinensis), Application (Hospitals, Clinics, Homecare), Testing Type (Microscopy, Serologic Tests, Proteomics Testing), Disease Type (Hepatitis, Diarrhea, Emaciation), Treatment Type (Drugs, Vaccines) Players and Region - Global Market Outlook to 2030

Capillariasis Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Capillariasis
Capillariasis is a form of parasitic disease that is found in humans, which is genera caused by two different kinds of species of Capillariasis namely Capillariasis hepatica and Capillaria philippinensis. C. hepatica is generally transferred through the means of fecal matter of any infected animals and can thereby lead to hepatitis. C. philippinensis is transferred through the means of ingesting infected small freshwater fish and can lead to diarrhea as well as emaciation. There are various medications that are used for the purpose of the treatment of parasitic diseases. Capillariasis is a parasitic disease caused by two different species of nematodes (roundworms) belonging to the genus Capillaria

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that European Players will contribute the maximum growth to Global Capillariasis market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc (United Kingdom), Roche Holding AG (Switzerland), CiplaMed (India), Lupin Limited (India), Teva Pharmaceuticals (Israel), Glenwood (United States), Sanofi S.A. (France), Romark (United States), Bayer (Germany), Valeant (United States), AstraZeneca (United Kingdom), Allergan Inc. (Ireland) and Pfizer (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Ben Pharmaceuticals (India), Healthy Life Pharma Private Limited (India), Novartis (Switzerland), Abbott Laboratories (United States) and Amneal Pharmaceuticals LLC (United States).

Segmentation Overview
AMA Research has segmented the market of Global Capillariasis market by Type (Capillaria Hepatica and Capillaria Philippinensis), Application (Hospitals, Clinics and Homecare) and Region.



On the basis of geography, the market of Capillariasis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Testing Type, the sub-segment i.e. Microscopy will boost the Capillariasis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Type, the sub-segment i.e. Hepatitis will boost the Capillariasis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Drugs will boost the Capillariasis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rise In Prevalence of Parasitic Infections and Rise in Awareness about Animal Health Care

Market Growth Drivers:
Increase in Awareness about Health Care and Parasitic Diseases and An Increase in Number of Animals

Challenges:
Lack of Awareness about the Diseases Caused In Underdeveloped Regions

Restraints:
Side Effects of the Drugs

Opportunities:
Rise In Awareness about Health Care and Government Initiatives and Modernization toward Improving Health Care Infrastructure

Market Leaders and their expansionary development strategies
In October 2023, Global consortium formed by academics, pharmaceutical companies, and NGOs unites to accelerate research and development efforts for improved capillariasis diagnostics, therapeutics, and vaccines
In November 2023, Clinical trial initiation for a novel antiparasitic drug for intestinal capillariasis, offering potential for more effective treatment options


Key Target Audience
Providers of Capillariasis, End Users, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Capillaria Hepatica
  • Capillaria Philippinensis
By Application
  • Hospitals
  • Clinics
  • Homecare
By Testing Type
  • Microscopy
  • Serologic Tests
  • Proteomics Testing

By Disease Type
  • Hepatitis
  • Diarrhea
  • Emaciation

By Treatment Type
  • Drugs
  • Vaccines

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Awareness about Health Care and Parasitic Diseases
      • 3.2.2. An Increase in Number of Animals
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness about the Diseases Caused In Underdeveloped Regions
    • 3.4. Market Trends
      • 3.4.1. Rise In Prevalence of Parasitic Infections
      • 3.4.2. Rise in Awareness about Animal Health Care
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Capillariasis, by Type, Application, Testing Type, Disease Type, Treatment Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Capillariasis (Value)
      • 5.2.1. Global Capillariasis by: Type (Value)
        • 5.2.1.1. Capillaria Hepatica
        • 5.2.1.2. Capillaria Philippinensis
      • 5.2.2. Global Capillariasis by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Homecare
      • 5.2.3. Global Capillariasis by: Testing Type (Value)
        • 5.2.3.1. Microscopy
        • 5.2.3.2. Serologic Tests
        • 5.2.3.3. Proteomics Testing
      • 5.2.4. Global Capillariasis by: Disease Type (Value)
        • 5.2.4.1. Hepatitis
        • 5.2.4.2. Diarrhea
        • 5.2.4.3. Emaciation
      • 5.2.5. Global Capillariasis by: Treatment Type (Value)
        • 5.2.5.1. Drugs
        • 5.2.5.2. Vaccines
      • 5.2.6. Global Capillariasis Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Capillariasis (Price)
      • 5.3.1. Global Capillariasis by: Type (Price)
  • 6. Capillariasis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Holding AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CiplaMed (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lupin Limited (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceuticals (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Glenwood (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi S.A. (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Romark (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Valeant (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. AstraZeneca (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Allergan Inc. (Ireland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Pfizer (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Capillariasis Sale, by Type, Application, Testing Type, Disease Type, Treatment Type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Capillariasis (Value)
      • 7.2.1. Global Capillariasis by: Type (Value)
        • 7.2.1.1. Capillaria Hepatica
        • 7.2.1.2. Capillaria Philippinensis
      • 7.2.2. Global Capillariasis by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Homecare
      • 7.2.3. Global Capillariasis by: Testing Type (Value)
        • 7.2.3.1. Microscopy
        • 7.2.3.2. Serologic Tests
        • 7.2.3.3. Proteomics Testing
      • 7.2.4. Global Capillariasis by: Disease Type (Value)
        • 7.2.4.1. Hepatitis
        • 7.2.4.2. Diarrhea
        • 7.2.4.3. Emaciation
      • 7.2.5. Global Capillariasis by: Treatment Type (Value)
        • 7.2.5.1. Drugs
        • 7.2.5.2. Vaccines
      • 7.2.6. Global Capillariasis Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Capillariasis (Price)
      • 7.3.1. Global Capillariasis by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Capillariasis: by Type(USD Million)
  • Table 2. Capillariasis Capillaria Hepatica , by Region USD Million (2018-2023)
  • Table 3. Capillariasis Capillaria Philippinensis , by Region USD Million (2018-2023)
  • Table 4. Capillariasis: by Application(USD Million)
  • Table 5. Capillariasis Hospitals , by Region USD Million (2018-2023)
  • Table 6. Capillariasis Clinics , by Region USD Million (2018-2023)
  • Table 7. Capillariasis Homecare , by Region USD Million (2018-2023)
  • Table 8. Capillariasis: by Testing Type(USD Million)
  • Table 9. Capillariasis Microscopy , by Region USD Million (2018-2023)
  • Table 10. Capillariasis Serologic Tests , by Region USD Million (2018-2023)
  • Table 11. Capillariasis Proteomics Testing , by Region USD Million (2018-2023)
  • Table 12. Capillariasis: by Disease Type(USD Million)
  • Table 13. Capillariasis Hepatitis , by Region USD Million (2018-2023)
  • Table 14. Capillariasis Diarrhea , by Region USD Million (2018-2023)
  • Table 15. Capillariasis Emaciation , by Region USD Million (2018-2023)
  • Table 16. Capillariasis: by Treatment Type(USD Million)
  • Table 17. Capillariasis Drugs , by Region USD Million (2018-2023)
  • Table 18. Capillariasis Vaccines , by Region USD Million (2018-2023)
  • Table 19. South America Capillariasis, by Country USD Million (2018-2023)
  • Table 20. South America Capillariasis, by Type USD Million (2018-2023)
  • Table 21. South America Capillariasis, by Application USD Million (2018-2023)
  • Table 22. South America Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 23. South America Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 24. South America Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 25. Brazil Capillariasis, by Type USD Million (2018-2023)
  • Table 26. Brazil Capillariasis, by Application USD Million (2018-2023)
  • Table 27. Brazil Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 28. Brazil Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 29. Brazil Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 30. Argentina Capillariasis, by Type USD Million (2018-2023)
  • Table 31. Argentina Capillariasis, by Application USD Million (2018-2023)
  • Table 32. Argentina Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 33. Argentina Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 34. Argentina Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 35. Rest of South America Capillariasis, by Type USD Million (2018-2023)
  • Table 36. Rest of South America Capillariasis, by Application USD Million (2018-2023)
  • Table 37. Rest of South America Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 38. Rest of South America Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 39. Rest of South America Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 40. Asia Pacific Capillariasis, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Capillariasis, by Type USD Million (2018-2023)
  • Table 42. Asia Pacific Capillariasis, by Application USD Million (2018-2023)
  • Table 43. Asia Pacific Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 44. Asia Pacific Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 45. Asia Pacific Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 46. China Capillariasis, by Type USD Million (2018-2023)
  • Table 47. China Capillariasis, by Application USD Million (2018-2023)
  • Table 48. China Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 49. China Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 50. China Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 51. Japan Capillariasis, by Type USD Million (2018-2023)
  • Table 52. Japan Capillariasis, by Application USD Million (2018-2023)
  • Table 53. Japan Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 54. Japan Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 55. Japan Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 56. India Capillariasis, by Type USD Million (2018-2023)
  • Table 57. India Capillariasis, by Application USD Million (2018-2023)
  • Table 58. India Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 59. India Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 60. India Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 61. South Korea Capillariasis, by Type USD Million (2018-2023)
  • Table 62. South Korea Capillariasis, by Application USD Million (2018-2023)
  • Table 63. South Korea Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 64. South Korea Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 65. South Korea Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 66. Taiwan Capillariasis, by Type USD Million (2018-2023)
  • Table 67. Taiwan Capillariasis, by Application USD Million (2018-2023)
  • Table 68. Taiwan Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 69. Taiwan Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 70. Taiwan Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 71. Australia Capillariasis, by Type USD Million (2018-2023)
  • Table 72. Australia Capillariasis, by Application USD Million (2018-2023)
  • Table 73. Australia Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 74. Australia Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 75. Australia Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Capillariasis, by Type USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Capillariasis, by Application USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 81. Europe Capillariasis, by Country USD Million (2018-2023)
  • Table 82. Europe Capillariasis, by Type USD Million (2018-2023)
  • Table 83. Europe Capillariasis, by Application USD Million (2018-2023)
  • Table 84. Europe Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 85. Europe Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 86. Europe Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 87. Germany Capillariasis, by Type USD Million (2018-2023)
  • Table 88. Germany Capillariasis, by Application USD Million (2018-2023)
  • Table 89. Germany Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 90. Germany Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 91. Germany Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 92. France Capillariasis, by Type USD Million (2018-2023)
  • Table 93. France Capillariasis, by Application USD Million (2018-2023)
  • Table 94. France Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 95. France Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 96. France Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 97. Italy Capillariasis, by Type USD Million (2018-2023)
  • Table 98. Italy Capillariasis, by Application USD Million (2018-2023)
  • Table 99. Italy Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 100. Italy Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 101. Italy Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 102. United Kingdom Capillariasis, by Type USD Million (2018-2023)
  • Table 103. United Kingdom Capillariasis, by Application USD Million (2018-2023)
  • Table 104. United Kingdom Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 105. United Kingdom Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 106. United Kingdom Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 107. Netherlands Capillariasis, by Type USD Million (2018-2023)
  • Table 108. Netherlands Capillariasis, by Application USD Million (2018-2023)
  • Table 109. Netherlands Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 110. Netherlands Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 111. Netherlands Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 112. Rest of Europe Capillariasis, by Type USD Million (2018-2023)
  • Table 113. Rest of Europe Capillariasis, by Application USD Million (2018-2023)
  • Table 114. Rest of Europe Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 115. Rest of Europe Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 116. Rest of Europe Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 117. MEA Capillariasis, by Country USD Million (2018-2023)
  • Table 118. MEA Capillariasis, by Type USD Million (2018-2023)
  • Table 119. MEA Capillariasis, by Application USD Million (2018-2023)
  • Table 120. MEA Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 121. MEA Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 122. MEA Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 123. Middle East Capillariasis, by Type USD Million (2018-2023)
  • Table 124. Middle East Capillariasis, by Application USD Million (2018-2023)
  • Table 125. Middle East Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 126. Middle East Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 127. Middle East Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 128. Africa Capillariasis, by Type USD Million (2018-2023)
  • Table 129. Africa Capillariasis, by Application USD Million (2018-2023)
  • Table 130. Africa Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 131. Africa Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 132. Africa Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 133. North America Capillariasis, by Country USD Million (2018-2023)
  • Table 134. North America Capillariasis, by Type USD Million (2018-2023)
  • Table 135. North America Capillariasis, by Application USD Million (2018-2023)
  • Table 136. North America Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 137. North America Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 138. North America Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 139. United States Capillariasis, by Type USD Million (2018-2023)
  • Table 140. United States Capillariasis, by Application USD Million (2018-2023)
  • Table 141. United States Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 142. United States Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 143. United States Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 144. Canada Capillariasis, by Type USD Million (2018-2023)
  • Table 145. Canada Capillariasis, by Application USD Million (2018-2023)
  • Table 146. Canada Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 147. Canada Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 148. Canada Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 149. Mexico Capillariasis, by Type USD Million (2018-2023)
  • Table 150. Mexico Capillariasis, by Application USD Million (2018-2023)
  • Table 151. Mexico Capillariasis, by Testing Type USD Million (2018-2023)
  • Table 152. Mexico Capillariasis, by Disease Type USD Million (2018-2023)
  • Table 153. Mexico Capillariasis, by Treatment Type USD Million (2018-2023)
  • Table 154. Capillariasis: by Type(USD/Units)
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Capillariasis: by Type(USD Million)
  • Table 169. Capillariasis Capillaria Hepatica , by Region USD Million (2025-2030)
  • Table 170. Capillariasis Capillaria Philippinensis , by Region USD Million (2025-2030)
  • Table 171. Capillariasis: by Application(USD Million)
  • Table 172. Capillariasis Hospitals , by Region USD Million (2025-2030)
  • Table 173. Capillariasis Clinics , by Region USD Million (2025-2030)
  • Table 174. Capillariasis Homecare , by Region USD Million (2025-2030)
  • Table 175. Capillariasis: by Testing Type(USD Million)
  • Table 176. Capillariasis Microscopy , by Region USD Million (2025-2030)
  • Table 177. Capillariasis Serologic Tests , by Region USD Million (2025-2030)
  • Table 178. Capillariasis Proteomics Testing , by Region USD Million (2025-2030)
  • Table 179. Capillariasis: by Disease Type(USD Million)
  • Table 180. Capillariasis Hepatitis , by Region USD Million (2025-2030)
  • Table 181. Capillariasis Diarrhea , by Region USD Million (2025-2030)
  • Table 182. Capillariasis Emaciation , by Region USD Million (2025-2030)
  • Table 183. Capillariasis: by Treatment Type(USD Million)
  • Table 184. Capillariasis Drugs , by Region USD Million (2025-2030)
  • Table 185. Capillariasis Vaccines , by Region USD Million (2025-2030)
  • Table 186. South America Capillariasis, by Country USD Million (2025-2030)
  • Table 187. South America Capillariasis, by Type USD Million (2025-2030)
  • Table 188. South America Capillariasis, by Application USD Million (2025-2030)
  • Table 189. South America Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 190. South America Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 191. South America Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 192. Brazil Capillariasis, by Type USD Million (2025-2030)
  • Table 193. Brazil Capillariasis, by Application USD Million (2025-2030)
  • Table 194. Brazil Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 195. Brazil Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 196. Brazil Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 197. Argentina Capillariasis, by Type USD Million (2025-2030)
  • Table 198. Argentina Capillariasis, by Application USD Million (2025-2030)
  • Table 199. Argentina Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 200. Argentina Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 201. Argentina Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 202. Rest of South America Capillariasis, by Type USD Million (2025-2030)
  • Table 203. Rest of South America Capillariasis, by Application USD Million (2025-2030)
  • Table 204. Rest of South America Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 205. Rest of South America Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 206. Rest of South America Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 207. Asia Pacific Capillariasis, by Country USD Million (2025-2030)
  • Table 208. Asia Pacific Capillariasis, by Type USD Million (2025-2030)
  • Table 209. Asia Pacific Capillariasis, by Application USD Million (2025-2030)
  • Table 210. Asia Pacific Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 211. Asia Pacific Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 212. Asia Pacific Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 213. China Capillariasis, by Type USD Million (2025-2030)
  • Table 214. China Capillariasis, by Application USD Million (2025-2030)
  • Table 215. China Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 216. China Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 217. China Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 218. Japan Capillariasis, by Type USD Million (2025-2030)
  • Table 219. Japan Capillariasis, by Application USD Million (2025-2030)
  • Table 220. Japan Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 221. Japan Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 222. Japan Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 223. India Capillariasis, by Type USD Million (2025-2030)
  • Table 224. India Capillariasis, by Application USD Million (2025-2030)
  • Table 225. India Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 226. India Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 227. India Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 228. South Korea Capillariasis, by Type USD Million (2025-2030)
  • Table 229. South Korea Capillariasis, by Application USD Million (2025-2030)
  • Table 230. South Korea Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 231. South Korea Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 232. South Korea Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 233. Taiwan Capillariasis, by Type USD Million (2025-2030)
  • Table 234. Taiwan Capillariasis, by Application USD Million (2025-2030)
  • Table 235. Taiwan Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 236. Taiwan Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 237. Taiwan Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 238. Australia Capillariasis, by Type USD Million (2025-2030)
  • Table 239. Australia Capillariasis, by Application USD Million (2025-2030)
  • Table 240. Australia Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 241. Australia Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 242. Australia Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 243. Rest of Asia-Pacific Capillariasis, by Type USD Million (2025-2030)
  • Table 244. Rest of Asia-Pacific Capillariasis, by Application USD Million (2025-2030)
  • Table 245. Rest of Asia-Pacific Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 246. Rest of Asia-Pacific Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 247. Rest of Asia-Pacific Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 248. Europe Capillariasis, by Country USD Million (2025-2030)
  • Table 249. Europe Capillariasis, by Type USD Million (2025-2030)
  • Table 250. Europe Capillariasis, by Application USD Million (2025-2030)
  • Table 251. Europe Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 252. Europe Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 253. Europe Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 254. Germany Capillariasis, by Type USD Million (2025-2030)
  • Table 255. Germany Capillariasis, by Application USD Million (2025-2030)
  • Table 256. Germany Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 257. Germany Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 258. Germany Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 259. France Capillariasis, by Type USD Million (2025-2030)
  • Table 260. France Capillariasis, by Application USD Million (2025-2030)
  • Table 261. France Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 262. France Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 263. France Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 264. Italy Capillariasis, by Type USD Million (2025-2030)
  • Table 265. Italy Capillariasis, by Application USD Million (2025-2030)
  • Table 266. Italy Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 267. Italy Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 268. Italy Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 269. United Kingdom Capillariasis, by Type USD Million (2025-2030)
  • Table 270. United Kingdom Capillariasis, by Application USD Million (2025-2030)
  • Table 271. United Kingdom Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 272. United Kingdom Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 273. United Kingdom Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 274. Netherlands Capillariasis, by Type USD Million (2025-2030)
  • Table 275. Netherlands Capillariasis, by Application USD Million (2025-2030)
  • Table 276. Netherlands Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 277. Netherlands Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 278. Netherlands Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 279. Rest of Europe Capillariasis, by Type USD Million (2025-2030)
  • Table 280. Rest of Europe Capillariasis, by Application USD Million (2025-2030)
  • Table 281. Rest of Europe Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 282. Rest of Europe Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 283. Rest of Europe Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 284. MEA Capillariasis, by Country USD Million (2025-2030)
  • Table 285. MEA Capillariasis, by Type USD Million (2025-2030)
  • Table 286. MEA Capillariasis, by Application USD Million (2025-2030)
  • Table 287. MEA Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 288. MEA Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 289. MEA Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 290. Middle East Capillariasis, by Type USD Million (2025-2030)
  • Table 291. Middle East Capillariasis, by Application USD Million (2025-2030)
  • Table 292. Middle East Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 293. Middle East Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 294. Middle East Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 295. Africa Capillariasis, by Type USD Million (2025-2030)
  • Table 296. Africa Capillariasis, by Application USD Million (2025-2030)
  • Table 297. Africa Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 298. Africa Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 299. Africa Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 300. North America Capillariasis, by Country USD Million (2025-2030)
  • Table 301. North America Capillariasis, by Type USD Million (2025-2030)
  • Table 302. North America Capillariasis, by Application USD Million (2025-2030)
  • Table 303. North America Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 304. North America Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 305. North America Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 306. United States Capillariasis, by Type USD Million (2025-2030)
  • Table 307. United States Capillariasis, by Application USD Million (2025-2030)
  • Table 308. United States Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 309. United States Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 310. United States Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 311. Canada Capillariasis, by Type USD Million (2025-2030)
  • Table 312. Canada Capillariasis, by Application USD Million (2025-2030)
  • Table 313. Canada Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 314. Canada Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 315. Canada Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 316. Mexico Capillariasis, by Type USD Million (2025-2030)
  • Table 317. Mexico Capillariasis, by Application USD Million (2025-2030)
  • Table 318. Mexico Capillariasis, by Testing Type USD Million (2025-2030)
  • Table 319. Mexico Capillariasis, by Disease Type USD Million (2025-2030)
  • Table 320. Mexico Capillariasis, by Treatment Type USD Million (2025-2030)
  • Table 321. Capillariasis: by Type(USD/Units)
  • Table 322. Research Programs/Design for This Report
  • Table 323. Key Data Information from Secondary Sources
  • Table 324. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Capillariasis: by Type USD Million (2018-2023)
  • Figure 5. Global Capillariasis: by Application USD Million (2018-2023)
  • Figure 6. Global Capillariasis: by Testing Type USD Million (2018-2023)
  • Figure 7. Global Capillariasis: by Disease Type USD Million (2018-2023)
  • Figure 8. Global Capillariasis: by Treatment Type USD Million (2018-2023)
  • Figure 9. South America Capillariasis Share (%), by Country
  • Figure 10. Asia Pacific Capillariasis Share (%), by Country
  • Figure 11. Europe Capillariasis Share (%), by Country
  • Figure 12. MEA Capillariasis Share (%), by Country
  • Figure 13. North America Capillariasis Share (%), by Country
  • Figure 14. Global Capillariasis: by Type USD/Units (2018-2023)
  • Figure 15. Global Capillariasis share by Players 2023 (%)
  • Figure 16. Global Capillariasis share by Players (Top 3) 2023(%)
  • Figure 17. Global Capillariasis share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. CiplaMed (India) Revenue, Net Income and Gross profit
  • Figure 24. CiplaMed (India) Revenue: by Geography 2023
  • Figure 25. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 26. Lupin Limited (India) Revenue: by Geography 2023
  • Figure 27. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 28. Teva Pharmaceuticals (Israel) Revenue: by Geography 2023
  • Figure 29. Glenwood (United States) Revenue, Net Income and Gross profit
  • Figure 30. Glenwood (United States) Revenue: by Geography 2023
  • Figure 31. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 33. Romark (United States) Revenue, Net Income and Gross profit
  • Figure 34. Romark (United States) Revenue: by Geography 2023
  • Figure 35. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bayer (Germany) Revenue: by Geography 2023
  • Figure 37. Valeant (United States) Revenue, Net Income and Gross profit
  • Figure 38. Valeant (United States) Revenue: by Geography 2023
  • Figure 39. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 41. Allergan Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 42. Allergan Inc. (Ireland) Revenue: by Geography 2023
  • Figure 43. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 44. Pfizer (United States) Revenue: by Geography 2023
  • Figure 45. Global Capillariasis: by Type USD Million (2025-2030)
  • Figure 46. Global Capillariasis: by Application USD Million (2025-2030)
  • Figure 47. Global Capillariasis: by Testing Type USD Million (2025-2030)
  • Figure 48. Global Capillariasis: by Disease Type USD Million (2025-2030)
  • Figure 49. Global Capillariasis: by Treatment Type USD Million (2025-2030)
  • Figure 50. South America Capillariasis Share (%), by Country
  • Figure 51. Asia Pacific Capillariasis Share (%), by Country
  • Figure 52. Europe Capillariasis Share (%), by Country
  • Figure 53. MEA Capillariasis Share (%), by Country
  • Figure 54. North America Capillariasis Share (%), by Country
  • Figure 55. Global Capillariasis: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Roche Holding AG (Switzerland)
  • CiplaMed (India)
  • Lupin Limited (India)
  • Teva Pharmaceuticals (Israel)
  • Glenwood (United States)
  • Sanofi S.A. (France)
  • Romark (United States)
  • Bayer (Germany)
  • Valeant (United States)
  • AstraZeneca (United Kingdom)
  • Allergan Inc. (Ireland)
  • Pfizer (United States)
Additional players considered in the study are as follows:
Ben Pharmaceuticals (India) , Healthy Life Pharma Private Limited (India) , Novartis (Switzerland) , Abbott Laboratories (United States) , Amneal Pharmaceuticals LLC (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 242 Pages 77 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Capillariasis Market Quantitative research analysis
Global Capillariasis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline plc (United Kingdom), Roche Holding AG (Switzerland), CiplaMed (India), Lupin Limited (India), Teva Pharmaceuticals (Israel), Glenwood (United States), Sanofi S.A. (France), Romark (United States), Bayer (Germany), Valeant (United States), AstraZeneca (United Kingdom), Allergan Inc. (Ireland) and Pfizer (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rise In Prevalence of Parasitic Infections " is seen as one of major influencing trends for Capillariasis Market during projected period 2023-2030.
The Capillariasis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Capillariasis Market Report?

Have a Query? Click Here

Other Related Reports

Multiple Myeloma Therapy Comprehensive Study by Type (Targeted Therapy, Chemotherapy, Radiotherapy, Bone Marrow Transplant), Application (Smouldering Multiple Myeloma, Active Multiple Myeloma), End-U...
$ 3350
Gynecologic Cancer Comprehensive Study by Type (Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer), Application (Hospital, Clinic, Other), Treatment (Chemotherapy, Rad...
$ 3650
Campylobacter Diagnostics Comprehensive Study by Type (Culture-based Diagnosis, Rapid Detection Tests (Immunological, Molecular, and Other )), End User (Hospitals, Private Laboratories, Independent P...
$ 3350
Brucellosis Comprehensive Study by Transmission (Raw Dairy Products, Inhaling Contaminated Air, Infected Blood & Body Fluids, Others), Diagnosis (Serological Tests, Molecular Techniques, Bone Marrow ...
$ 3750
Carrion's Disease Comprehensive Study by Antibiotics (Chloramphenicol, Azithromycin, Erythromycin, Ciprofloxacin, Rifampin, Macrolides), Stages (Acute Phase, Chronic Phase), End User (Hospitals, Clin...
$ 3500
Campylobacteriosis Comprehensive Study by Application (Hospitals, Clinics, Private Laboratories, Independent Physician Chambers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Onl...
$ 3750